(LINA) – The World Health Organization (WHO) has announced the effectiveness of the clinical trials of the first vaccine against Ebola, the outbreak of which claimed more than 11,000 lives in West Africa.
According to the UN agency, as part of the trials, the immunogen rVSV-ZEBOV was tested with very positive results in 5,837 people in Guinea, the nation from which the epidemic spread to Sierra Leone and Liberia in 2014.
“Among those who received the vaccine, no case of Ebola was recorded within 10 days or more after the inoculation,” Marie -Paule Kieny, WHO Assistant Director-General for Health Systems and Innovation reported.
The research also covered 6,000 additional volunteers who did not receive the injection and were followed up by WHO teams who reported 23 cases of the disease in this group.
According to Kieny, although these convincing results came too late for those who died in the Ebola epidemic in West Africa, “when the next outbreak appears, we will have a defense.”
However, it still remains to be determined how long the immunity with this vaccine lasts and if only one dose is required to be effective.
According to a press statement, a report on the vaccine will be submitted for the registration in the United States and European Union and a response is expected in 2018, which will allow the medicine to be marketed.
The vaccine rVSV-ZEBOV was developed by the Public Health Agency of Canada and is produced by the US pharmaceutical company Merck.
Ebola is a disease caused in humans by the Ebola virus and usually its symptoms -fever, sore throat, and headache – begin between two days and three weeks after contracting the virus.
Usually, this is followed by nausea, vomiting, and diarrhoea along with hepatic and renal failure.